158 - CCON SPOTLIGHT: CARDIOVASCULAR DISEASE IN PATIENTS WITH CANCER: A COMPETENCY FOR ALL CARDIOLOGISTS?

Friday, October 28, 2022

2:00 PM – 3:00 PM EDT

Location: Room 214

Target Audience: Trainee (clinical), Cardiac technicians & nurses

Co-Chair(s)

Paaladinesh Thavendiranathan, MD, FRCPC

Director, Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, TGH
Toronto General Hospital
University of Toronto
Toronto, Ontario, Canada
CB

Christine Brezden-Masley, MD PhD

Medical Oncologist
Toronto, Ontario, Canada

Presenter(s)

Margot K. Davis, MD MSc FRCPC (she/her/hers)

Clinical Associate Professor
University of British Columbia
University of British Columbia
Vancouver, British Columbia, Canada
Husam M. Abdel-Qadir, MD, PhD

Cardiologist-Scientist
Women’s College Hospital, University Health Network
Toronto, Ontario, Canada
Darryl P. Leong, MBBS, MPH, PhD

Associate Professor
McMaster University
McMaster University
Hamilton, Ontario, Canada

Planning Committee Member(s)

OC

Oscar Calvillo-Arguelles

Cardiologist
Sudbury, Ontario, Canada
NM

Nagareh Mousavi

Cardiologist
Montreal, Quebec, Canada
EP

Edith Pituskin

Associate Professor, Canada Research Chair (Tier 2) Chronic Disease, Faculty of Nursing
Edmonton, Alberta, Canada
CP

Coleen Power

Cardiooncology Nurse Practitioner
Toronto, Ontario, Canada
HS

Henry Su, MD

Cardiooncology Fellow, Peter Munk Cardiac Center
toronto, Ontario, Canada
Kibar Yared, MD FRCPC

Cardiologist
Scarborough Health Network
University of Toronto Medical School
Toronto , Ontario, Canada

Presenter(s)

Paaladinesh Thavendiranathan, MD, FRCPC

Director, Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, TGH
Toronto General Hospital
University of Toronto
Toronto, Ontario, Canada

Learning Objectives:

At the conclusion of this session, participants will be able to:

identify drugs associated with HF, risk stratification and prevention strategies, and treatment options for heart failure in patients receiving potentially cardiotoxic cancer therapy;
identify cancer drugs and risk factors associated with arrhythmias and describe challenges associated with anticoagulation of patients with cancer;
describe the role of immunotherapy in contemporary cancer management, potential cardiovascular complications, and treatment strategies; and
identify risk factors and drivers of CAD in patients with cancer with the discussion of the role of a potential new risk factors – Clonal Hematopoiesis of Indeterminate Potential (CHIP).

This CardioOncology session will cover some of the most common and contemporary issues in the field. This will include therapies associated with heart failure, arrhythmias, myocarditis, and coronary disease. The session will describe risk factors, diagnostic and management strategies, and specific considerations particularly relevant in patients with cancer. The session will include presentation from Oncology and CardioOncology faculty.